FDA approval has been given, however, to metreleptin, an analog of leptin, for treating lipodystrophy (Araujo-Vilar and Santini, 2019) because of its proven efficacy in treating leptin deficiency disease compared to its lack of efficacy in treating common obesity with hyperleptinemia. This evidence concerns the gene LEP and Obesity.